Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

被引：38
作者：
Clerico, Marinella [1 ]
De Mercanti, Stefania [1 ]
Artusi, Carlo Alberto [1 ]
Durelli, Luca [1 ]
Naismith, Robert T. [2 ]
机构：
[1] Univ Torino, Clin & Biol Sci Dept, Neurol Unit, San Luigi Gonzaga Hosp, Gonzole 10, I-10043 Orbassano, Italy
[2] Washington Univ, Dept Neurol, St Louis, MO USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 06期
关键词：
Multiple sclerosis; alemtuzumab; herpes virus; cytomegalovirus; cytomegalovirus reactivation; multiple sclerosis treatment; CHRONIC LYMPHOCYTIC-LEUKEMIA; CONTROLLED PHASE-3 TRIAL; THERAPY; MANAGEMENT; DISEASE;
D O I：
10.1177/1352458516688350
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.
引用
收藏
页码：874 / 876
页数：3
相关论文
共 10 条
  • [1] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Arnold, Douglas L.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Fisher, Elizabeth
    Brinar, Vesna V.
    Giovannoni, Gavin
    Stojanovic, Miroslav
    Ertik, Bella I.
    Lake, Stephen L.
    Margolin, David H.
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1819 - 1828
  • [2] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
    Coles, Alasdair J.
    Twyman, Cary L.
    Arnold, Douglas L.
    Cohen, Jeffrey A.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Miller, Tamara
    Fisher, Elizabeth
    Sandbrink, Rupert
    Lake, Stephen L.
    Margolin, David H.
    Oyuela, Pedro
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1829 - 1839
  • [3] The evolving role of alemtuzumab in management of patients with CLL
    Faderl, S
    Coutré, S
    Byrd, JC
    Dearden, C
    Denes, A
    Dyer, MJS
    Gregory, SA
    Gribben, JG
    Hillmen, P
    Keating, M
    Rosen, S
    Venugopal, P
    Rai, K
    [J]. LEUKEMIA, 2005, 19 (12) : 2147 - 2152
  • [4] Phase II study of alerntuzurnab in chronic lymphoproliferative disorders
    Ferrajoli, A
    O'Brien, SM
    Cortes, JE
    Giles, FJ
    Thomas, DA
    Faderl, S
    Kurzrock, R
    Lerner, S
    Kontoyiannis, DP
    Keating, MJ
    [J]. CANCER, 2003, 98 (04) : 773 - 778
  • [5] Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis
    Hartung, Hans-Peter
    Aktas, Orhan
    Boyko, Alexey N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 22 - 34
  • [6] Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    Moreton, P
    Kennedy, B
    Lucas, G
    Leach, M
    Rassam, SMB
    Haynes, A
    Tighe, L
    Oscier, D
    Fegan, C
    Rawstron, A
    Hillmen, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2971 - 2979
  • [7] Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzamab
    O'Brien, Susan M.
    Keating, Michael J.
    Mocarski, Edward. S.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02) : 125 - 130
  • [8] Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
    Rai, KR
    Freter, CE
    Mercier, RJ
    Cooper, MR
    Mitchell, BS
    Stadtmauer, EA
    Santábarbara, P
    Wacker, B
    Brettman, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3891 - 3897
  • [9] Alemtuzumab for Multiple Sclerosis
    Willis, Mark D.
    Robertson, Neil P.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)
  • [10] Wray S, 2013, ANN M CONS MULT SCLE
1